Results from two large trials investigating the impact of spironolactone oncardiovascular deaths and hospitalizations should be published in the near futurefrom the Spironolactone Initiation Registry Randomized Interventional Trial inHeart Failure with Preserved Ejection Fraction (SPIRRIT-HF) [82] and theSpironolactone In The Treatment of Heart Failure (SPIRIT-HF) trials [83].Furthermore, compared to traditional MRAs, non-steroidal MRAs are emerging asdrugs with higher selectivity for mineralocorticoid receptors and withoutsex–steroid-related side effects [84]. Here, NR3C2 is linked to hydrops fetalis.